Atika Capital Management LLC Sells 15,900 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Atika Capital Management LLC lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,100 shares of the medical equipment provider's stock after selling 15,900 shares during the period. Atika Capital Management LLC owned about 0.08% of Lantheus worth $5,108,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Lantheus by 16.8% during the fourth quarter. Russell Investments Group Ltd. now owns 16,955 shares of the medical equipment provider's stock worth $1,517,000 after buying an additional 2,443 shares in the last quarter. Aviva PLC raised its position in Lantheus by 17.1% in the 4th quarter. Aviva PLC now owns 7,105 shares of the medical equipment provider's stock valued at $636,000 after purchasing an additional 1,037 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Lantheus in the fourth quarter worth $459,000. Resona Asset Management Co. Ltd. acquired a new position in Lantheus in the fourth quarter worth $440,000. Finally, Riverwater Partners LLC increased its position in Lantheus by 102.9% in the 4th quarter. Riverwater Partners LLC now owns 11,182 shares of the medical equipment provider's stock valued at $1,000,000 after acquiring an additional 5,671 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on LNTH. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. Truist Financial raised their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

NASDAQ:LNTH traded up $1.43 during trading hours on Friday, hitting $99.94. The stock had a trading volume of 222,635 shares, compared to its average volume of 893,946. Lantheus Holdings, Inc. has a one year low of $59.56 and a one year high of $126.89. The company has a market cap of $6.84 billion, a price-to-earnings ratio of 16.63 and a beta of 0.20. The business's 50 day moving average is $93.80 and its 200-day moving average is $95.67.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.